Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)-positive or -unknown metastatic breast cancer. Phase II and III trials have demonstrated that first-line therapy with toremifene, 60 mg/d, is as effective and as well tolerated as tamoxifen (Nolvadex), 20 or 40 mg/d, in such patients. To date, phase III trials have fatted to show a statistically significant advantage of higher toremifene doses over standard doses of tamoxifen in these women. Studies appeared to indicate minimal efficacy of high toremifene doses in women with ER-negative tumors, but the number of patients studied was small. Although results of some trials of high-dose (240 mg/d) toremifene in tamoxifen-"refractory" patients were negative, other trials that included prolonged (≥ 6 months) stable disease as an indication of clinical benefit yielded positive results.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalOncology
Volume12
Issue number3 SUPPL. 5
StatePublished - Dec 1 1998

Fingerprint

Toremifene
Phase III Clinical Trials
Phase II Clinical Trials
Tamoxifen
Breast Neoplasms
Estrogen Receptors
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer. / Vogel, Charles.

In: Oncology, Vol. 12, No. 3 SUPPL. 5, 01.12.1998, p. 9-13.

Research output: Contribution to journalArticle

@article{0c6b8cc0137c4a919e8a1c65805302b7,
title = "Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer",
abstract = "Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)-positive or -unknown metastatic breast cancer. Phase II and III trials have demonstrated that first-line therapy with toremifene, 60 mg/d, is as effective and as well tolerated as tamoxifen (Nolvadex), 20 or 40 mg/d, in such patients. To date, phase III trials have fatted to show a statistically significant advantage of higher toremifene doses over standard doses of tamoxifen in these women. Studies appeared to indicate minimal efficacy of high toremifene doses in women with ER-negative tumors, but the number of patients studied was small. Although results of some trials of high-dose (240 mg/d) toremifene in tamoxifen-{"}refractory{"} patients were negative, other trials that included prolonged (≥ 6 months) stable disease as an indication of clinical benefit yielded positive results.",
author = "Charles Vogel",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "12",
pages = "9--13",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3 SUPPL. 5",

}

TY - JOUR

T1 - Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer

AU - Vogel, Charles

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)-positive or -unknown metastatic breast cancer. Phase II and III trials have demonstrated that first-line therapy with toremifene, 60 mg/d, is as effective and as well tolerated as tamoxifen (Nolvadex), 20 or 40 mg/d, in such patients. To date, phase III trials have fatted to show a statistically significant advantage of higher toremifene doses over standard doses of tamoxifen in these women. Studies appeared to indicate minimal efficacy of high toremifene doses in women with ER-negative tumors, but the number of patients studied was small. Although results of some trials of high-dose (240 mg/d) toremifene in tamoxifen-"refractory" patients were negative, other trials that included prolonged (≥ 6 months) stable disease as an indication of clinical benefit yielded positive results.

AB - Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)-positive or -unknown metastatic breast cancer. Phase II and III trials have demonstrated that first-line therapy with toremifene, 60 mg/d, is as effective and as well tolerated as tamoxifen (Nolvadex), 20 or 40 mg/d, in such patients. To date, phase III trials have fatted to show a statistically significant advantage of higher toremifene doses over standard doses of tamoxifen in these women. Studies appeared to indicate minimal efficacy of high toremifene doses in women with ER-negative tumors, but the number of patients studied was small. Although results of some trials of high-dose (240 mg/d) toremifene in tamoxifen-"refractory" patients were negative, other trials that included prolonged (≥ 6 months) stable disease as an indication of clinical benefit yielded positive results.

UR - http://www.scopus.com/inward/record.url?scp=0001777491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001777491&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0001777491

VL - 12

SP - 9

EP - 13

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 3 SUPPL. 5

ER -